Abstract:Rett syndrome1 (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females, with an incidence of 1 in 10,000–15,000 (ref. 2). Patients with classic RTT appear to develop normally until 6–18 months of age, then gradually lose speech and purposeful hand use, and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements3. After initial regression, the condition stabilizes and patients usually survive into adulthood. As RTT occurs almost exclusively in females, it has been proposed that RTT is caused by an X-linked dominant mutation with lethality in hemizygous males3,4,5,6,7,8. Previous exclusion mapping studies using RTT families mapped the locus to Xq28 (refs 6,9,10,11). Using a systematic gene screening approach, we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT. MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (refs 12,13). In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD). In two affected half-sisters of a RTT family, we found segregation of an additional missense mutation not detected in their obligate carrier mother. This suggests that the mother is a germline mosaic for this mutation. Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.

Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

Loss of MeCP2 in Cholinergic Neurons Causes Part of RTT-like Phenotypes Via Α7 Receptor in Hippocampus

MeCP2 Deficiency Alters the Response Selectivity of Prefrontal Cortical Neurons to Different Social Stimuli

MeCP2 Deficiency Impairs Motor Cortical Circuit Flexibility Associated with Motor Learning

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome.

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

Mutations in MECP2 Exon 1 in Classical Rett Patients Disrupt MECP2_e1 Transcription, but Not Transcription of MECP2_e2

Genome-Wide Analysis Reveals Methyl-Cpg-Binding Protein 2-Dependent Regulation Of Micrornas In A Mouse Model Of Rett Syndrome

MECP2 Mutation Spectrum and Its Clinical Characteristics in a Chinese Cohort